Top

Published in:

Open Access 19-05-2022 | Sudden Cardiac Death

Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction

Authors: Ahmed Muhammed, Mohamed Abdelazeem, Mohamed Gamaleldin Elewa, Mohamed Sharief, Ahmed Ammar

Published in: Heart Failure Reviews | Issue 1/2023

Abstract

Sudden cardiac death (SCD) and significant ventricular arrhythmias in patients with dilated cardiomyopathy (DCM) have been markedly reduced over the last couple of decades as a result of the advances in pharmacological and non-pharmacological treatment. Primary prevention implantable cardioverter-defibrillator (ICD) plays an important role in the treatment of patients at risk of SCD caused by ventricular arrhythmias. However, the arrhythmic risk stratification in patients with DCM remains extremely challenging, and the decision for primary prevention ICD implantation based on left ventricular ejection fraction (LVEF) solely appears to be insufficient. This review provides an update on current evidence for primary prevention ICD implantation, arrhythmic risk stratification, and left ventricular reverse remodeling (LVRR) prediction in patients with DCM in addition to most recent guideline recommendations for primary prevention ICD implantation in DCM patients and a proposed multiparametric algorithm based on arrhythmic risk stratification and left ventricular reverse remodeling (LVRR) prediction to better identify patients who are likely to benefit from primary prevention ICD.

Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al (2008) Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 29(2):270–276CrossRef

Weintraub RG, Semsarian C, Macdonald P (2017) Dilated cardiomyopathy. Lancet 390(10092):400–14. Available from: http://www.thelancet.com/article/S0140673616317135/fulltext

Hershberger RE, Hedges DJ, Morales A (2013) Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 10(9):531–47. Available from: https://www.nature.com/articles/nrcardio.2013.105

Pathak RK, Sanders P, Deo R (2018) Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy. Eur Heart J 39(31):2859–2866CrossRef

Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F et al (2021) Improved risk stratification for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 77(23):2890–2905CrossRef

&NA (2003) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. Surv Anesthesiol 47(2):73

Lee KL, Hafley G, Fisher JD, Gold MR, Prystowsky EN, Talajic M et al (2002) Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. Available from: http://www.circulationaha.org

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352. Available from: www.nejm.org

Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K et al (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105(12):1453–1458CrossRef

10.

Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP et al (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350. Available from: www.nejm.org

11.

Long YX, Hu Y, Cui DY, Hu S, Liu ZZ (2021) The benefits of defibrillator in heart failure patients with cardiac resynchronization therapy: a meta-analysis. PACE - Pacing Clin Electrophysiol 44(2):225–234CrossRef

12.

Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375(13):1221–1230CrossRef

13.

Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J et al (2017) Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 136(19):1772–1780CrossRef

14.

Barakat AF, Saad M, Elgendy AY, Mentias A, Abuzaid A, Mahmoud AN et al (2017) Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials. BMJ Open 7(6):e016352. Available from: https://bmjopen.bmj.com/content/7/6/e016352

15.

Sutton MGSJ, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E (2006) Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology. Circulation 113(2):266–72. Available from: https://doi.org/10.1161/CIRCULATIONAHA.104.520817

16.

Gras M, Bisson A, Bodin A, Herbert J, Babuty D, Pierre B et al (2020) Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. EP Eur 22(8):1224–33. Available from: https://0811eqsag-1103-y-https-academic-oup-com.mplbci.ekb.eg/europace/article/22/8/1224/5864442

17.

van der Lingen ALCJ, Timmer SAJ, Allaart LJH, Rijnierse MT, van de Ven PM, van Rossum AC et al (2019) The benefit of prophylactic implantable cardioverter defibrillator implantation in asymptomatic heart failure patients with a reduced ejection fraction. Am J Cardiol 124(4):560–6. Available from: https://doi.org/10.1016/j.amjcard.2019.05.026

18.

Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL et al (2003) Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 41(10):1707–1712CrossRef

19.

Cannatà A, De Angelis G, Boscutti A, Normand C, Artico J, Gentile P et al (2020) Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy beyond ejection fraction. Heart 106(9):656–664CrossRef

20.

Briongos‐Figuero S, Estévez A, Pérez ML, Martínez‐Ferrer JB, García E, Viñolas X et al (2020) Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy. ESC Hear Fail 7(1):279. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083467/

21.

Amorim S, Campelo M, Martins E, Moura B, Sousa A, Pinho T et al (2016) Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy. Rev Port Cardiol 35(5):253–260CrossRef

22.

Zabel M, Sticherling C, Willems R, Lubinski A, Bauer A, Bergau L et al (2019) Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation. ESC Hear Fail 6(1):182–93. Available from: https://pubmed.ncbi.nlm.nih.gov/30299600/

23.

Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH (2014) Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 63(18):1879–1889CrossRef

24.

Upton G, Cook I (2008) A Dictionary of Statistics. A Dict Stat

25.

JA M, JC M, SK P, WJ M, CH L, AJ C et al (2003) Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108(1):54–9. Available from: https://pubmed.ncbi.nlm.nih.gov/12821550/

26.

Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W et al (2017) Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): study protocol for a randomized controlled trial. Ann Noninvasive Electrocardiol 22(4)

27.

Kawakami S, Takaki H, Hashimoto S, Kimura Y, Nakashima T, Aiba T et al (2016) Utility of high-resolution magnetocardiography to predict later cardiac events in nonischemic cardiomyopathy patients with normal QRS duration. Circ J 81(1):44–51. Available from: https://pubmed.ncbi.nlm.nih.gov/27853097/

28.

Korhonen P, Väänänen H, Mäkijärvi M, Katila T, Toivonen L (2001) Repolarization abnormalities detected by magnetocardiography in patients with dilated cardiomyopathy and ventricular arrhythmias. J Cardiovasc Electrophysiol 12(7):772–7. Available from: https://pubmed.ncbi.nlm.nih.gov/11469426/

29.

Lachlan T, He H, Sharma K, Khan J, Rajappan K, Morley-Davies A et al (2020) MAGNETO cardiography parameters to predict future sudden cardiac death (MAGNETO-SCD) or ventricular events from implantable cardioverter defibrillators: study protocol, design and rationale. BMJ Open 10(10). Available from: https://pubmed.ncbi.nlm.nih.gov/33040013/

30.

Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure 375(13):1221–30. Available from: https://doi.org/10.1056/NEJMoa1608029

31.

Aimo A, Januzzi JL, Vergaro GGV, Ripoli A, Latini R, Masson S et al (2018) Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. Circulation 137(3):286–97. Available from: https://pubmed.ncbi.nlm.nih.gov/29335288/

32.

Lupó J, De Antonio M, Vila J, Peñ Afiel J, Galá A, Zamora E et al (2021) Development of a novel heart failure risk tool: the Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator). Available from: www.plosone.org

33.

Marrow BA, Cook SA, Prasad SK, McCann GP (2020) Emerging techniques for risk stratification in nonischemic dilated cardiomyopathy: JACC review topic of the week. J Am Coll Cardiol 75(10):1196–1207CrossRef

34.

Hammersley DJ, Halliday BP (2020) Sudden cardiac death prediction in non-ischemic dilated cardiomyopathy: a multiparametric and dynamic approach. Curr Cardiol Rep 22(9)

35.

Ebert M, Wijnmaalen AP, de Riva M, Trines SA, Androulakis AFA, Glashan CA et al (2020) Prevalence and prognostic impact of pathogenic variants in patients with dilated cardiomyopathy referred for ventricular tachycardia ablation. JACC Clin Electrophysiol 6(9):1103–14. Available from: https://research.rug.nl/en/publications/prevalence-and-prognostic-impact-of-pathogenic-variants-in-patien

36.

Verdonschot JAJ, Hazebroek MR, Wang P, Sanders-van Wijk S, Merken JJ, Adriaansen YA et al (2018) Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. Circ Heart Fail 11(11):e005220. Available from: https://pubmed.ncbi.nlm.nih.gov/30571196/

37.

Corden B, Jarman J, Whiffin N, Tayal U, Buchan R, Sehmi J et al (2019) Association of titin-truncating genetic variants with life-threatening cardiac arrhythmias in patients with dilated cardiomyopathy and implanted defibrillators. JAMA Netw Open 2(6):e196520–e196520. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2736938

38.

Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G (2018) Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 20(2):228–39. Available from: https://pubmed.ncbi.nlm.nih.gov/29271570/

39.

Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P et al (2013) Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol 61(1):54–63CrossRef

40.

Kimura Y, Okumura T, Morimoto R, Kazama S, Shibata N, Oishi H et al (2021) A clinical score for predicting left ventricular reverse remodelling in patients with dilated cardiomyopathy. ESC Hear Fail 8(2):1359–1368CrossRef

41.

M M, D S, M A, F N, B P, G B et al (2015) Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long‐term follow‐up: does real healing exist? J Am Heart Assoc 4(1). Available from: https://pubmed.ncbi.nlm.nih.gov/25587018/

42.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol

43.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726CrossRef

44.

Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB et al (2021) Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 18(3):169–93. Available from: https://kyushu-u.pure.elsevier.com/en/publications/myocarditis-and-inflammatory-cardiomyopathy-current-evidence-and-

45.

Topkara VK, Garan AR, Fine B, Godier-Furnémont AF, Breskin A, Cagliostro B et al (2016) Myocardial recovery in patients receiving contemporary left ventricular assist devices: results from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Circ Heart Fail 9(7). Available from: https://www.ncbi.nlm.nih.gov//pmc/articles/PMC4943678/

46.

D’Ambrosio A, Patti G, Manzoli A, Di Sciascio G, Sinagra G, Di Lenarda A et al (2001) The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 85(5):499–504. Available from: https://pubmed.ncbi.nlm.nih.gov/11302994/

47.

48.

Choi JO, Kim EY, Lee GY, Lee SC, Park SW, Kim DK et al (2013) Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy. Circ J 77(2):462–9

49.

Tobita T, Nomura S, Fujita T, Morita H, Asano Y, Onoue K et al (2018) Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci 8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/29386531/

50.

Marume K, Noguchi T, Tateishi E, Morita Y, Miura H, Nishimura K et al (2020) Prognosis and clinical characteristics of dilated cardiomyopathy with family history via pedigree analysis. Circ J 84(8):1284–93. Available from: https://tohoku.pure.elsevier.com/en/publications/prognosis-and-clinical-characteristics-of-dilated-cardiomyopathy-

51.

Wouter Jukema J, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, De Bie MK et al (2019) Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients: the prospective, randomized, controlled ICD2 trial. Circulation 139(23):2628–38. Available from: http://ahajournals.org

52.

Dendale P, Scherrenberg M, Sivakova O, Frederix I (2019) Prevention: from the cradle to the grave and beyond. Eur J Prev Cardiol 26(5):507–11. Available from: https://doi.org/10.1177/2047487318821772

53.

Al-Gobari M, Al-Aqeel S, Gueyffier F, Burnand B (2018) Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. BMJ Open 8(7):e021108. Available from: https://bmjopen.bmj.com/content/8/7/e021108

54.

Wong JA, Roberts JD, Healey JS (2021) The optimal timing of primary prevention implantable cardioverter-defibrillator referral in the rapidly changing medical landscape. Can J Cardiol 37(4):644–54. Available from: http://www.onlinecjc.ca/article/S0828282X21000696/fulltext

55.

Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE (2010) Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 56(5):392–406. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523221/

56.

Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D (2019) Effects of the angiotensin‐receptor neprilysin inhibitor on cardiac reverse remodeling: meta‐analysis. J Am Hear Assoc Cardiovasc Cerebrovasc Dis 8(13). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662364/

57.

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424CrossRef

58.

Greene SJ, Fonarow GC, DeVore AD et al (2019) Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol 73(19):2365–2383. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197490/

59.

McMurray JJV, Packer M (2021) How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine. Circulation 875–7

60.

Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Bloma N, Borggrefe M, Camm J et al (2015) 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the Europea. Eur Heart J 36(41):2793–2867lCrossRef

61.

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al (2017) AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Vol. 138. Circulation 2018:272–391

62.

Van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-Van Ast JF, Van Der Kooi AJ et al (2012) Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol 59(5):493–500CrossRef

63.

Ribera A, Giménez E, Oristrell G, Osorio D, Marsal JR, García-Pérez L et al (2022) Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Rev Esp Cardiol (Engl Ed) 75(1):12–21. Available from: https://pubmed.ncbi.nlm.nih.gov/34099431/

Title: Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction
Authors: Ahmed Muhammed
Mohamed Abdelazeem
Mohamed Gamaleldin Elewa
Mohamed Sharief
Ahmed Ammar
Publication date: 19-05-2022
Publisher: Springer US
Keywords: Sudden Cardiac Death
Cardiomyopathy
ICD Implantation
ICD Implantation
ICD Implantation
Implantable Cardioverter Defibrillator
Implantable Cardioverter Defibrillator
Published in: Heart Failure Reviews / Issue 1/2023
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-022-10246-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Clinical outcomes of implantable cardioverter-defibrillator therapy in noncompaction cardiomyopathy: a systematic review and meta-analysis

Echocardiographic scores for biventricular repair risk prediction of congenital heart disease with borderline left ventricle: a review

Endomyocardial biopsy in the clinical context: current indications and challenging scenarios

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin

Clinical application of CMR in cardiomyopathies: evolving concepts and techniques

Illustrative review of cardiac amyloidosis by multimodality imaging

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page